Bristol-Myers Squibb (BMY) said Monday that its phase 3 Odyssey-HCM trial, which evaluated Camzyos in adults with symptomatic New York Heart Association class II-III non-obstructive hypertrophic cardiomyopathy, did not meet its dual primary endpoints.
The trial failed to show a statistically significant difference from placebo in changes from baseline to week 48 in both the Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score and peak oxygen consumption.
No new safety signals were observed, the company added.
Shares of Bristol-Myers Squibb were down 2% in after-hours trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。